2015 Fiscal Year Final Research Report
Search for the biomarkers for the survival of patients of ovariacn clear cell adenocarcinoma
| Project/Area Number |
25462616
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Dokkyo Medical University (2015)
Jikei University School of Medicine (2013) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YANAIHARA Nozomu 東京慈恵会医科大学, 医学部, 講師 (20349624)
YAMADA Kyosuke 東京慈恵会医科大学, 医学部, 准教授 (30230452)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 卵巣癌 / 明細胞腺癌 / バイオマーカー / IL-6 / IL-&R |
|---|
| Outline of Final Research Achievements |
The multivariate analysis indicated that non-optimal staging surgery predicted worse recurrence-free survival (RFS) than the optimal staging surgery in stages IA/IC1 ovarian clear cell adenocarcinoma (CCC) patients by a retrospective review of 165 stage I CCC patients. The multivariate analysis indicated that advanced stages, hyperhemoglobinemia, thrombocytosis, higher creatinine level, and higher C-reactive protein level predicted worse PFS by a retrospective review of 98 CCC patinets.
A total of 84 CCC cases collected from primary surgical specimens were evaluated by the immunohistochemical analysis for IL-6R and phosphorylated Stat3, and we found that high IL-6R expression correlated with poor patient survival by the multivariate analyses, suggesting that IL-6/IL-6R signaling pathway could be implicated in the progression of CCC.
Inhibition of endogenous IL-6R including tocilizumab in CCC cells did reduce cell invasion ability and restored their response to cytotoxic reagent.
|
| Free Research Field |
婦人科腫瘍学
|
